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Abstract
MALDI mass spectrometry imaging (MALDI-MSI) is currently used for clinical applications, such as biomarker
identification, particularly for the study of solid tumors. The ability to map specific compounds that have been
determined to be biomarkers and therapeutic targets is relevant for the evaluation of the efficacy of targeted
therapies. This article describes a new method called Spectro-ImmunoHistoChemistry (SIHC), which combines
the use of specific antibodies against markers and mass spectrometric imaging in the MS/MS mode. SIHC is
based on direct primary antibody–antigen recognition, trypsin digestion of the antibody overlaying the markers
of interest in the tissue section, and MALDI-MSI of the tryptic peptides generated from the antibody. This
approach has both clinical and pharmacological applications. First, it can be used as a cross-validation method to
monitor the presence specifically of a marker in a tissue section. Second, SIHC could potentially be used as a
novel technology for tracking specific antibodies after in vivo injection for anti-cancer treatments. Additionally,
SIHC could enable novel clinical applications of MSI, such as monitoring the efficacy of cytotoxic antibody
treatments.
Introduction
Since the concept of mapping molecular compoundsdirectly on tissues using MALDI ion sources was pro-
posed at the end of the 1990s (Caprioli et al., 1997), MALDI
mass spectrometry imaging (MALDIMSI) has been used for a
wide array of clinical applications (Chaurand et al., 2004;
Cornett et al., 2006; Fournier et al., 2003, 2008; Franck et al.,
2009b; Lemaire, 2005b; McDonnell et al., 2010; Schwamborn
et al., 2007; Seeley and Caprioli, 2008; Stauber et al., 2006). A
decade of instrumentation and sample preparation develop-
ment has led to the optimal detection and spatial resolution
for mapping compounds in tissue sections (Angel and Ca-
prioli, 2013; Gagnon et al., 2012). These developments, com-
bined with the use of the appropriate computational tools for
data processing, have led to the discovery of biomarkers for
diverse pathologies, including cancer (Bonnel et al., 2011;
Djidja et al., 2009; McCombie et al., 2005; Stauber et al., 2008;
Trede et al., 2012). MALDI MSI technology provides access to
the molecular profiles of benign and malignant sections of
solid tumors (Aichler et al., 2013; Balluff et al., 2010, 2011; El
Ayed et al., 2010; Elsner et al., 2012; Flatley et al., 2013; Franck
et al., 2009b, 2010; Gustafsson et al., 2012; Jones et al., 2013;
Lemaire et al., 2005b, 2007a; Longuespee et al., 2012a, 2012b;
McDonnell et al., 2010; Meding et al., 2012a, 2012b; Meding
and Walch, 2013; Ray-Coquard et al., 2012; Wisztorski et al.,
2013). The application of this method is particularly useful for
identifying biomarkers in biopsies from early stages of cancer,
when the disease is still treatable and the 5-year survival rate
of managed patients remains high (Longuespe´e et al., 2012a,
2012b; Lowe et al., 2013; Meding et al., 2013).
MALDI MSI technology allows for the assessment of
hundreds of biomolecular compounds from different molec-
ular classes, and it would be greatly beneficial to be able to
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validate the presence of specific molecular markers in the
cancerous sections of tissues using this technology instead of
classical microscopy devices. Indeed, the MALDI-MSI-based
discovery of a biomarker has to be validated by a comple-
mentary method, such as immunohistochemistry, which re-
lies on the use of an antibody that specifically targets the
marker of interest. By detecting this specific antibody bymass
spectrometry, especially byMALDI-MSI, the validation of the
presence of newly discovered biomarkers could be conducted
in the same laboratory, without the need for microscopy. This
would have a high impact on disease monitoring by enabling
the evaluation of the presence of the compounds of interest in
diseased tissues. In this context, MSI could support the eval-
uation of targeted therapies in preclinical or clinical trials.
Finally, a potential application of this method is the moni-
toring of antibody delivery of cytotoxic treatments. Currently,
it is unknown whether the antibodies used to enhance the
recruitment of cytotoxic antibodies are distributed in a tumor
section. It is important to determine how deeply the antibody
can penetrate the tumor and at what concentration it is
present. Thismethodwould enable the detection of antibodies
through their tryptic peptides after enzymatic digestion in
tissues and could be directly applicable to clinical trials.
Several years ago, we developed and patented a method
called Tag-Mass for mapping MSI-specific targets (Gagnon
et al., 2012; Lemaire et al., 2007a; Stauber et al., 2009). One
application of the Tag-Mass technology is MSI based and uses
photocleavable, tagged antibody probes grafted to specific
antibodies for a given biomarker (Gagnon et al., 2012; Lemaire
et al., 2005a, 2007b; Stauber et al., 2009). This strategy relies on
the design of specific antibodies that are used for immuno-
histochemistry (IHC), which are linked to tag peptides of
known sequences (Gagnon et al., 2012) and can be detected by
mass spectrometry. After IHCpreparation, the presence of the
linked peptides is mapped on the surface of the tissue, and the
identity of each antibody is determined by the MS/MS anal-
ysis of these linked peptides. Although this method is highly
efficient and reproducible, the design of the linked antibodies
remains expensive.
In this work, we present a simple and fast method, called
Spectro-ImmunoHistoChemistry (SIHC), which combines
IHC andMALDI MSI without requiring the design of specific
antibodies to image targeted antigens. In the SIHC method,
tryptic digests of the primary antibodies are directly mapped
against the tissue marker of interest. This is achieved by
performing an on-tissue enzymatic digestion after primary
antibody binding to the tissue section. Resulting tryptic pep-
tides are then detected directly from the tissue and followed
by imaging. In the present article, the proof-of-concept of the
SIHC method is presented using ovarian cancer as a clinical
model. Additionally, using MALDI MSI, we have discovered
a potential novel marker for this pathology: the C-terminal
fragment of the activator of the immunoproteasome PA28
(Reg Alpha) (El Ayed et al., 2010; Lemaire et al., 2005, 2007a;
Longuespee et al., 2012a). The RegAlpha C-terminal fragment
is one of the markers of immunosuppressive events that occur
during the early phases of disease progression (El Ayed et al.,
2010; Lemaire et al., 2005b, 2007a; Longuespe´e et al., 2012a;
2012b). Using SIHC, we validate the statement that Reg-
Alpha is found at the early stages of all ovarian cancerous




a-Cyano-4-hydroxycinnamic acid (CHCA), trifluoroacetic
acid (TFA), aniline, PBS, ammonium bicarbonate, dithio-
threitol, iodoacetamide, bovine serum albumin, and triton
were obtained from Sigma-Aldrich (Saint-Quentin Fallavier,
France). Trypsinwas obtained from Promega (Charbonnieres,
France). Acetonitrile p.a., methanol p.a., ethanol, and acetone
were provided by Biosolve B.V. (Valkensvaard, Netherlands).
Polyclonal antibodies against Reg Alpha were purchased
from Invitrogen (Illkirch, France). Mounting media for tissues
stainings was provided by Vectashield. Histological glass
slides were purchased from Thermo Fisher (Illkirch, France).
Samples
Tissues were obtained with informed consent and institu-
tional review board approval (CCPPRBM Lille: CP 05/83)
from patients undergoing any ovarian tumor resection at
Hospital Jeanne de Flandre of Centre Hospitalier Uni-
versitaire de Lille. Three fresh, frozen tissues were used for
this investigation, corresponding to stage I to stage IV en-
dometrioid and serous cancer tissues. Patient informationwas
collected, including gender, age, treatment received before
and after the surgery, extent of the surgery, current status
(alive, alive with progressive disease, or deceased), cause of
death if applicable, and survival time from the time of the
original pathological diagnosis. Samples were collected at the
time of the surgery, immediately frozen at - 50C, in cold
isopentane, and stored at - 80C until analysis.
Tissue preparation
Tenmicrometer-thick frozen biopsy sectionswere cut using
a cryostat and thaw-mounted on histological glass slides.
Tissues were then dried in a dessicator. The sections were
washed for 1min in acetone, 15 sec in a solution of 70% eth-
anol, 15 sec in a solution of 95% ethanol and, finally, 1min in
chloroform (Lemaire et al., 2006).
Hematoxylin eosin safran staining. For hematoxylin
eosin safran staining (HES), the sections were heated for 5min,
colored with hematoxylin for 3min, rinsed with water, bathed
twice in a solution of 156mL of 95% EtOH, 44mL of H2O, and
80lL ofHCl (1N), and then bathed inwater. Then, the samples
were bathed in 35%NH4OH in 200mLH2O, washed for 5min
with water, and bathed in 80% ethanol. Next, the sections were
colored with eosin for 10 sec and bathed twice with 95% etha-
nol and twice with 100% ethanol. After staining with safran
(10 g/L in 100% EtOH) for 6min, the slides were bathed twice
in 100% EtOH and once in xylene for 1min. Histopathologic
diagnoses were made from these H&E-stained sections by the
pathologist (Olivier Kerdraon) without knowledge of the
original clinical diagnosis. Consecutive sections were used for
SIHC and the HES staining.
Immunohistochemistry of the Reg-alpha Cter fragment in
serous ovarian cancer tissues for the SIHC procedure. The
prepared tumor tissue sections were incubated at room tem-
perature with 500 lL of buffer (0.1M PBS, 1% BSA, 1% normal
goat serum, and 0.05% Triton X100) for 30min. The same
buffer was used to dilute the Reg-alpha antibody solution
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(1:100; Zymed Laboratories, Invitrogen, ref. 38-2400). The
tissues were incubated with the primary antibody in the
buffer overnight at 4C. After incubation, tissue sections were
rinsed three times for 10min with PBS and twice for 5min
with HPLC-grade water. The tissues were then rinsed three
additional times for 5min with ultrapure water to remove
salts from the buffer, and the sections were then dried at room
temperature before trypsin application.
Molecular mass spectrometry analyses
Trypsin deposition and digestion. Two modes of trypsin
deposition were used for the on-tissue trypsin digestion of
antibodies, micro-spraying, and micro-spotting.
For trypsin deposition by micro-spraying, 300 lL of a so-
lution of 40 lg/mL of trypsin that was diluted in 50mM
NH4HCO3 was sprayed using a vibrational micro-sprayer
(ImagePrep, Bruker Daltonics, Germany), with 13 cycles of
1.5 sec of spraying, 240 sec of incubation, and 30 sec of drying.
For trypsin deposition by micro-spotting, a piezoelectric
automated micro-spotting device (CHIP 1000, Shimadzu,
Kyoto, Japan) was used. Digestion was performed using
20 lg/mL trypsin in 50mM NH4HCO3 in a final volume of
12.5 nL (Franck et al., 2009a). The distance between two spots
was set at 250 lm.
Matrix deposition. The matrix deposition mode was cho-
sen according to the trypsin deposition method. CHCA/ani-
line solid ionic matrix was used for these experiments.
CHCA/aniline was prepared with an equivalent molarity of
CHCA and aniline in ACN/0.1% TFA, 7:3, v/v in H2O. For
CHCA/aniline micro-spraying, a specific method of deposi-
tion was created. In the first phase, the deposition was ini-
tialized with short nebulization and incubation times to spray
small droplets of matrix, giving rise to small crystals. Spray
and incubation times were then programmed at longer du-
rations in the following steps to spray larger droplets (Bonnel
et al., 2011). For microspotting, a total of 20 nL of 10mg/mL
CHCA/aniline was placed on the same spots where trypsin
was deposited (Franck et al., 2009a).
On-tissue digestion and direct analysis. The digestion
reaction was prolonged for sprayed samples by incubating
the tissue sections in incubation chambers previously de-
signed by our team (Longuespe´e et al.) for 2 h, as the spraying
time itself is not long enough for a sufficient digestion reac-
tion. After 2 h, the tissue was immediately dried by desicca-
tion and the matrix was deposited.
After the on-tissue digestion and matrix deposition, direct
tissue analysis was performed on the MALDI LTQ Orbitrap
XL (Thermo Scientific, Bremen, Germany) to assess the spec-
tral quality resulting from the digestion andmatrix deposition
efficiencies. Approximately 20 scans per digested point in the
FTMS mode in the mass range 600–4000m/z with a nominal
mass resolution of 100000 at m/z 400 were acquired.
MALDI imaging. The imageswere acquiredusingaMALDI
LTQ Orbitrap XL (Thermo Scientific, Bremen, Germany).
Spectrawere acquired using the Xcalibur 2.0.7 SP1 software
(Thermo Fisher Scientific, Bremen, Germany). The LTQ Or-
bitrap instrument was operated in the positive ion mode over
a high mass range (m/z = 600–4000). The instrument was
equipped with an intermediate pressure (75 mTorr) MALDI
source using a nitrogen laser (MNL 100; Lasertechnik Berlin),
providing an output at 337 nm with a maximum energy of
80lJ per pulse and a repetition rate of 60Hz. The Orbitrap
analyzer was used for MS data acquisition, with a mass re-
solving power of 30,000 FWHM. Automatic gain control was
turned off, and other data acquisition conditions were as
follows: laser power per pulse of 10lJ, 25 laser pulses per
spectra, and two scans averaged per pixel. The image recon-
structions were performed using the ImageQuest software.
The distance between raster points was set to 250lm. Image
analysis and data visualization were performed with the
Imagequest1.0.1 software (Thermo Fisher Scientific, Bremen,
Germany).
Antibody chain separation and identification
Gel electrophoresis. Heavy and light chains of the anti-C-
terminal Reg-alpha polyclonal antibodies were reduced using
10mM DTT, and cysteine residues were subsequently alky-
lated using 100 lL of iodoacetamide at 15mM. Electrophor-
esis gels were prepared at 12% for the separation gel and 4%
for the concentration gel. Migration proceeded for 2 h at 230
volts. After migration, the gels were stained with Coomassie
Blue for 24 h. After staining, the gels were bathed in distilled
water for 1 day.
In-gel digestion of antibody heavy and light chains.
Before trypsin digestion, the gels were washed in water for 2
days. Bands of interest were cut and rinsed with 100 lL of
50mM ammonium bicarbonate buffer and then with 50mM
ammonium bicarbonate buffer containing water:acetonitrile
2:8 v/v (pH 8) to remove the remaining Coomassie Blue and
allow shrinking of the gel pieces. Then, the gel fragments were
incubated overnight with 50 lL of 50mM trypsin in 50mM
ammonium bicarbonate buffer. After vortexing, the super-
natant was retained, and 100 lL of ACN:water 1:1 v/v was
added to the gel fragments. After vortexing, the resulting
supernatant was recovered and mixed with the first super-
natant. The solution was then dried in a vacuum concentrator,
and the peptides were suspended in 20lL of water/2% ace-
tonitrile/0.1% of a solution of 98% formic acid.
Mass spectrometry of digested peptides from antibody
chains. After digestion and matrix deposition, peptide
analysis was performed on a MALDI LTQ Orbitrap XL pre-
viously used for MS or MS/MS analyses. Approximately 20
scans per digested point in FTMSmode in the range 600–4000
with a nominal mass resolution of 100000 at m/z 400 were
acquired.
Results
Our group previously developed and patented a method
for mapping specific compounds in ovarian cancer tissues
(Fournier et al., 2006; Lemaire et al., 2005a, 2007b). In this
method, called Tag Mass, an antibody is linked to a laser-
cleavable peptide of known sequence. The image of the m/z
ratio of this peptide is generated, and the peptide’s sequence is
determined by MS/MS (Lemaire et al., 2007b). Here, another
method to screen for the presence of antibodies raised against
specific markers in tissue sections is described. This technol-
ogy relies on the direct detection of antibodies on tissues
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through their tryptic cleavage patterns. Only a characteriza-
tion step is needed before performing SIHC assays. We de-
cided to focus our efforts on developing amethod for tracking
specific compounds that bind to the C-terminal fragments of
Reg-alpha. We previously discovered this compound by
MALDI MSI and found that it was specifically present in
ovarian cancer biopsies (Lemaire et al., 2007a; Longuespee
et al., 2012a).
SpectroImmunoHistoChemistry procedure
The workflow of the method is presented in Figure 1. The
proposedmethod relies on a combination of IHC andMSI and
is named Spectro-ImmunoHistoChemistry (SIHC). Because
native antibodies are difficult to detect due to their high mass,
trypsin digestion prior to MALDI detection is recommended.
Heavy and light chains can be separated following reduction
and alkylation (R&A) (Fig. 1). The antibody used to test this
approach is the polyclonal antibody raised against the C-
terminal fragment of the 11S proteasome activator complex,
named PA28 or Reg-alpha. We have already validated this
marker as being indicative of ovarian cancer tissues with IHC
(Longuespe´e et al., 2012a). Thus, as shown in Figure 1A (see
inset SDS-PAGE, lane 2), without R&A, the anti-C-terminal
fragment of Reg-alpha antibodies is detected at 150 kDa, with
a large smear from 75 to 150 kDa revealing that the proteins
are denatured but that the heavy and light chains may remain
linked. As shown in Figure 1A, in lanes 3 and 4 of the SDS-
PAGE gel, the antibody chains are separated after R&A (light
chains at 25 kDa and heavy chains at 50 kDa).We also observe
large smeared regions for the heavy and light chains. The
appearance of the smears reveals the large heterogeneity of
glycoforms in polyclonal antibodies for heavy and light
chains.We digested each chain groupwith trypsin to generate
a general profile of the antibody (Fig. 2A). These experiments
were conducted three times. Peptide mass fingerprints from
gel electrophoresis band digests were then compared with
those obtained after the SIHC procedure on cancerous regions
of ovarian tissue (Fig. 2B).
In contrast with classical immunohistochemistry assays,
only the primary antibody is required for SIHC because the
detection is performed during the MSI analysis. The primary
antibody was placed on the tissue section and incubated
overnight at 4C. The slice was then subjected to a washing
procedure before R&A, followed by an on-tissue trypsin
digestion. For SIHC analysis, the step consisting of the incu-
bation with a secondary antibody, as in classical immuno-
histochemistry, was skipped and a layer of matrix was
FIG. 1. SIHC workflow. (A) SDS-PAGE gel of the antibody directed against the C-terminal
fragment of Reg alpha in the presence or absence of DTT. Separate antibody heavy and light
chains were then digested with trypsin before MALDI-MS analysis for specific PMF identi-
fication. In parallel, (B) corresponds to a classical incubation of the primary antibody per-
formed on top of the tissue slice. DTT, trypsin, and the matrix were deposited on the tissue in
succession before imaging by MALDI MS. The MS/MS profiles of the tryptic peptides shared
between the tissue and the in-gel digests were compared, with specific images of the ions
corresponding with the digested antibody chains used to determine antibody localization.
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immediately deposited for the desorption-ionization of the
digested fragments andMSImapping (Fig. 1B). Asmentioned
above, the principle of this approach is very simple and relies
on a direct comparison between the profile of the digested
antibody (the peptide mass fingerprint, or PMF) obtained
after in-gel trypsin digestion (Fig. 2A) and the PMF of di-
gested peptides found in the tissue after antibody incubation,
followed by trypsin digestion (Fig. 2B). For a better compar-
ison, all trypsin-digested fragments were removed from the
obtained peaks list, andwe focused our attention on a selected
window (.e., for ions ranging from m/z ratios of 900 to 2100).
The antibody recognized the biomarker from the complete
protein and the Cter fragment protein. Moreover, these ana-
lyses were performed on a MALDI LTQ Orbitrap instrument,
allowing for the acquisition of highly resolved mass spectra.
In this analysis, we detected several common ions between
electrophoresis gels and MALDI images (i.e., ions at m/z ra-
tios of 951.62, 1033.72, 1051.73, 1165.76, 1334.91, 1448.95, and
1562.98).
SIHC validation in MS mode
Validation on Stage IV serous ovarian carcinoma sam-
ples. To validate the SIHC protocol, we analyzed Stage IV
serous ovarian carcinoma (OVC) tissues using a MALDI-Or-
bitrap instrument. Ions at m/z ratios of 1165.76, 1334.91,
1448.95, and 1562.98, corresponding to tryptic peptides of the
C-terminal fragment of the Reg-alpha antibody, were tracked
through the cancerous zones of the biopsies (Fig. 3A). All
specific ions were detected in the tumor region and, to a lesser
extent, in the benign region, which agrees with previous
work. This result showed that the antibody specifically rec-
ognized the biomarker at the level of the epithelial cells in both
the nucleus and the cytoplasm in the carcinoma region and
only in the nucleus in benign tissue (Lemaire et al., 2007a;
Longuespe´e et al., 2012a). From 376 samples, this marker re-
flects a prevalence of 77.66– 8.77% with a correlation coeffi-
cient value of 0.601 ( p> 0.001) between OVC and benign
tissue (Longuespe´e et al., 2012a). This result confirms the ef-
fectiveness of this strategy. This difference in ion detection
relates to ion intensity detection in the PMF after gel electro-
phoresis (Fig. 2A) or on-tissue digestion (Fig. 2B) and can be
explained by ionization differences due to the peptide struc-
ture and ion suppression. Moreover, some ions are preferen-
tially detected in certain stages and grades of OVC, but in the
majority of the cases, the ions at m/z ratios of 1165.76,
1334.91, 1448.94, and 1562.98 are detected.
Validation on early stages of serous ovarian carcinoma
samples. The SIHC protocol was then applied to early stage
OVC (Stage Ia, Fig. 4 and Stage Ic, Fig. 3B). Patient samples
FIG. 2. Comparison of the MALDI MS spectra of heavy and light chains of anti-reg alpha after either
electrophoresis gel digestion (A) or on-tissue digestion using a stage I serous ovarian cancer tissue (B). An
asterisk (*) indicates the ions in common. The blue arrow and line indicate the benign zone, and the red arrow
and line indicate the cancerous zone.
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with stage Ic OVC had both cancerous cells and a benign
region (Fig. 3B). Ions at m/z ratios of 1448.94 and 1562.98
were detected solely in cancerous cells and not in the benign
region (Fig. 3B). A margin region from endometrioid stage Ia
OVC [i.e., a small region covering both benign and carcinoma
tissue, was selected (Fig. 4B)]. After microspotting for the
deposition of trypsin and the ionic solid matrix (HCCA/ani-
line), the tissuewas analyzed in thismargin region to compare
the cancerous and benign zones in a more restricted window
(Fig. 4A). Under these conditions, some specific ions corre-
sponding to digested peptides of the heavy or light antibody
chains (ions at m/z ratios of 951.64, 1051.73, 1165.76, 1448.94,
1523.8, and 1562.98) were imaged (Fig. 4C). These ions were
detected in the cancerous portion but not in the healthy por-
tion of the tissue section, confirming the specificity and se-
lectivity of the SIHC technique (Fig. 4C).
Validation of SIHC in MS/MS mode
To support the data observed in theMSmode, images were
then obtained by tracking the signatures of ions obtained in
the MS/MS mode. Selected daughter ions can be mapped
using thismethod, and known peptides of the antibody can be
automatically detected and mapped based on the MS/MS
signature. Figure 5 presents the molecular images based on
the fragments of the ion at anm/z value of 1523.79 detected in
the tumor region of the margin (Fig. 4C). MSI images of ions
were observed at m/z ratios of 786.08, 890.4, 1147.01, 1261.6,
and 1523.79. All of these daughter ions were present in the
tumor region but not in the benign part of the tissue section.
These data establish that the SIHC technique can be used in
both the MS and MS/MS modes.
Discussion
These experiments demonstrated that IHC and MALDI
MSI methods can be combined to enable powerful detection
and mapping of antibodies in biological samples. Specific
MALDI MSI of an antibody can now be performed in an in-
expensive assay that is not time intensive. We propose a
method for the cross-validation of the presence of marker
compounds in tissues, using MALDI MSI as the method to
detect primary antibodies. This allows for the direct confir-
mation of molecular localization without the use of secondary
antibodies and microscopes, as in this approach, the mass
spectrometer acts as a microscope. This opens new
FIG. 3. MALDI molecular images (250lm) of common m/z values determined by electro-
phoresis gel digestion and digestion of Reg Alpha antibody on ovarian carcinoma tissue (red
line). Trypsin and the matrix (HCCA/aniline) were sprayed using an automatic sprayer.
Specific ions from trypsin-digested antibody chains were detected in the cancerous area. These
experiments were performed on a MALDI LTQ Orbitrap. (A) Stage IV OVC. Ions detected
have m/z ratios of 1165.76, 1334.91, 1448.94, and 1562.98. (B) Stage Ic OVC. Ions detected have
m/z ratios of 1448.94 and 1562.9. The blue arrow and line indicate the benign zone, and the red
arrow and line indicate the cancerous zone.
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possibilities for pharmacological assays, such as monitoring
the efficiency of the targeting of cytotoxic antibodies through
tissue inspection. The presence and localization of therapeutic
antibodies in solid tumors remain important areas of interest
for investigators in this field of pharmacological develop-
ment. This new method may enable the specific tracking
of therapeutic or anti-marker antibodies in tissues and pro-
vide information on their presence in cancerous sections of
biopsies.
A few years ago, we developed a novel technology, named
Tag-Mass, which allowed for the monitoring of biomarkers in
tissues. Tag-Mass involves a modified probe bearing a re-
porter group that is used in MALDI-MSI. The image of the
marker is then indirectly generated from the probe (Lemaire
et al., 2007b). This technology is compatible with all types of
probes, including mRNA, antibodies, or even lectins or ap-
tamers. It is then possible to image, with high selectivity,
mRNA, antigens, oligosaccharides (including glycosylated
proteins), and drugs, respectively (Gagnon et al., 2012). In the
Tag-mass workflow, MALDI-MSI is combined with histo-
logical techniques, including In Situ Hybridization (ISH) and
immunohistochemistry (IHC). This method allowed for the
exploration of both the transcriptome and the proteome in the
same tissue section by MALDI MSI in response to a single
compound or a number of compounds in multiplex analyses.
The latest development regarding this technology is a new
UTP-tag based on click-chemistry for tracking in MALDI MSI
miRNAs.
Considering this new study, SIHC and Tag-mass appear to
be two complementary technologies for use in research and
clinical settings. The great advantage of using the SIHC ap-
proach is its compatibility with any polyclonal or monoclonal
antibodies for the detection of a given marker. Indeed, Tag
Mass requires the design of a grafted antibody for the recog-
nition of a specific antigen. Here, the approach does not re-
quire any chemical design to tag antibodies. This approach
relies on polyclonal antibodies, which are known to be highly
specific for a given marker of interest. In this study, we de-
cided to focus our efforts on the C-terminal fragment of PA28,
also known as Reg Alpha. This marker was extensively
studied by our team and found to be present in great amounts
in the cytoplasm of cancerous cells and the nucleus of normal
FIG. 4. MALDI molecular images (250 lm) of common m/z values found by electrophoresis gel
digestion and digestion on stage Ia endometrioid OVC tissue at the margin between the cancerous
and benign tissue (red line). Trypsin and matrix (HCCA/aniline) were spotted using an automatic
piezoelectric head spotter before MALDI MSI analysis (Franck et al., 2009a). Specific ions from
trypsin digested antibody chains were detected in the cancerous area. These experiments were
performed on a MALDI LTQ Orbitrap. (A) Average mass spectrum recorded in the margin area.
The arrows indicate the ions corresponding to reg alpha antibody chains after trypsin digestion
and molecular MSI were performed. (B) Patient section stained with HES. The margin is indicated
as a blue box. (C) Molecular images obtained by MSI of the ions at m/z ratios of 951.64, 1051.73,
1165.76, 1523.8, and 1562.98.
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ovarian cells within the same biopsy (Lemaire et al., 2007a).
We demonstrated via IHC that Cter-Reg-alpha was present in
great amounts in the cancerous areas of ovarian biopsies, and
this was also highlighted by mass spectrometric profiling,
classical MALDI Imaging and Tag Mass MALDI Imaging (El
Ayed et al., 2010). Here, we validated a strong mass spectro-
metric signal for thismarker in the cancerous zone and a slight
signal in the normal tissue area, corresponding to the recog-
nition of the Cter part of full length PA28. In the future, we can
expect increases in the imaging resolution of MALDI as new
instruments are developed or improved; for example, new
ionization sources coupled to highly resolutive analyzers,
such as the Orbitrap (Schober et al., 2012). With this type of
instrumental evolution, it may be possible to distinguish be-
tween antibody fragment signals from the nucleus in normal
areas and signals from the cytoplasm in cancerous cells.
Finally, an extension of this approach is the multiplexed
analysis of the markers of interest throughout the tissue sec-
tion. This analysis could validate the diagnostic application of
this approach by using antibodies either directed against the
normal or cancerous areas of a biopsy section.
Currently, SpectroImmunoHistoChemistry will aid labo-
ratories using mass spectrometry that aim to explore clinical
applications, to cross-validate the presence of discovered an-
tibodies in tissue sections and to conduct histopathological
investigations on large numbers of tissue sections.
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